Advanced Immunological Treatment and Research Medical Center

Scientific Advisory Board


Dr. Francesco Marincola - MD

Dr. Marincola is considered one of the worlds leading tumor Immunologists. He was the Chief of the Infectious Disease and Immunogenetics Section in the Department of Transfusion Medicine at the Clinical Center of the National Institute of Health in Bethesda. He was founder and serves as Editor-in-Chief, Journal of Translational Medicine and ASHI Quarterly, senior editor for the Journal of the American Society for Histocompatibility and Immunogenetics, and editor for a variety of academic journals, including Immunotherapy, Journal of Immunotherapy, Journal of Immunology, Tumori, Clinical Cancer Research, Biological Therapy, and Cancer Immunology and Immunotherapy. He is also a founding member of the Society for Immunotherapy of Cancer.

Dr. Marincola has done extensive research in tumor immunology by developing strategies for studying tumor-host interactions in the context of human genetic polymorphism and cancer heterogeneity. During his tenure as a Senior Staff Scientist with the NCI Surgery Branch, Dr. Marincola investigated the identification of the algorithm responsible for tumor rejection by immune cells particularly in the context of metastatic melanoma. In particular, the focus of his research is the optimization of strategies to study clinical material during the conduct of clinical trials. The NIH Immunogenetics laboratory is recognized nationally and internationally for the cutting edge technologies applied for the study of genetic materials at the genomic, transcriptional, epigenetic and mutational level.

Dr. Thomas Ichim, PhD. (Honorary Member)

Dr. Ichim has extensive experience with stem cell therapy and cellular product development through FDA regulatory pathways. Dr. Ichim spent over 7 years as the President and Chief Scientific Officer of Medistem, developing and commercializing a novel stem cell, the Endometrial Regenerative Cell, through drug discovery, optimization, preclinical testing, IND filing, and up through Phase II clinical trials with the FDA. Subsequent to the acquisition of Medistem by Intrexon,  Dr. Ichim was brought on to the parent company in its cell engineering unit as Vice President of Cellular Therapy. Thomas Ichim hopes to greatly add to the value of Batu Biologics by leveraging his existing contacts and experience in product development, regulatory filings, and business development. He is the author of 116 papers.

Dr. Ichim is the founder of Batu Biologics, named after his mother who survived 19 years with cancer. He developed his first patent at 19 years old using ozone to treat his mother’s Leukemia. He is the inventor of Vallovax which is also a vaccine that he made for his mother. Dr. Ichim is a genius in his field and his heart is focused on curing cancer.

Dr. Vijay Mahant, MS, PhD. 

Dr. Mahant graduated from LUT in the United Kingdom and received his second post-doctorate from MD Anderson in Houston TX.  Dr. Mahant is a scientist with over 30 years of experience in immune and molecular diagnostics.  He has held executive positions and he is founder/co-founder of diagnostic companies with diverse experiences in Research and Development including Auto Genomics, Medi-Lite and Qualigen. He is the inventor of the “New Generation” ultra-sensitive TSH test for prostate cancer.

Dr. Mahant’s work can be seen all over the world in leading cancer institutions using his cutting edge genetic and diagnostic equipment. He has been on the forefront of the liquid biopsy and circulating tumor cell movement. His passion is to find ways to match tumors with specific drugs that might be off label and to create even better early detection diagnostic tests.

Dr. Phillip S. Kim PhD.

Dr. Kim was awarded the human genetics fellowship by the National Institute of Health (NIH) at the  Cedar Sinai Medical Center. His research focused on the development of gene-therapy model via hematopoietic-stem cell mediated gene transfer and the development of ‘Geno-dynamics’ system to investigate gene function.

At Prometheus he led oncology and gastroenterology research teams to develop technologies, platforms and services for personalized/ targeted diagnostic applications with prognostic, predictive and monitoring utilities for oncology and autoimmune diseases. 

His work included  managing planning & execution of technical projects, clinical trials, science and technology communications, research collaborations & KOL (Key Opinion Leader) relationships, and publications.

He is the inventor of the immune pod which is positioned to address critical unmet need in oncology clinic by activating patient’s autologous immune cells specific for individual’s tumor for effective and safe cellular therapy without complex cellular manipulation. Minimally invasive approach using ‘Immuno-Pod’ maximizes tumor specific immune cell activation by exposing otherwise inaccessible tumor in vivo to contiguous ‘synthetic met’ ex vivo seamlessly integrated for each patient.

Dr. Kim’s valuable insight at CHIPSA will help guide decisions for precision medicine and specific immune response for all patients.